Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board
29 Luglio 2021 - 5:45PM
Business Wire
Danièle Guyot-Caparros, outgoing Chairwoman,
remains an independent member of the Board of Directors and Chair
of the Audit Committee
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First
North: ONXEO), « Onxeo », a clinical-stage biotechnology company
specializing in the development of innovative drugs targeting tumor
DNA Damage response (DDR) in oncology, today announced the
appointment of Dr Shefali Agarwal as the Company’s Chairwoman of
the Board of Directors. Danièle Guyot-Caparros, outgoing
Chairwoman, remains an independent member of the Board of Directors
and Chair of the Audit Committee.
Dr. Shefali Agarwal, physician by training, is the Chief Medical
and Development Officer at Epizyme, Inc, which develops novel
epigenetic therapies for cancer and other serious diseases, where
she leads global clinical development and regulatory strategy.
Prior to joining Epizyme in 2018, Dr. Agarwal held leadership
positions including clinical development and operations, and
medical and regulatory affairs. In particular, she led for Tesaro,
the clinical development and registration of the PARP inhibitor
ZEJULA® (niraparib) in ovarian cancer.
In addition, Dr. Agarwal is a member of the Board of Directors
of three U.S. biotechnology companies, ITB Med (private), Gritstone
Bio (NASDAQ: GRTS) and Fate Therapeutics (Nasdaq: FATE). She was
appointed as an independent director of Onxeo in June 2021.
Shefali Agarwal, incoming Chairwoman of the Board of
Directors of Onxeo, comments: "I am very honored to be
appointed with this new role on the Board of Directors of Onxeo and
would like to thank all its members for the trust they have placed
in me. I have been impressed by the innovative science and unique
platform of Onxeo as well as by the management team. I look forward
to sharing my experience in global development to the benefit of
the Company’s promising pipeline and bringing innovative and
effective medicine to cancer patients in need”.
Danièle Guyot-Caparros, outgoing Chairwoman, added: "The
Company is preparing to take a new strategic step, with the
implementation of an ambitious clinical program and a reinforced
presence in the United States. I am convinced that Dr. Agarwal's
expertise and in-depth knowledge of the global biotech world will
be a real asset for Onxeo and I look forward to continuing to
support Onxeo in achieving its ambitious goals.”
Judith Greciet, Chief Executive Officer of Onxeo,
concludes: "I would like to acknowledge Danièle Guyot-Caparros'
remarkable contribution to Onxeo since 2013, the year she was first
appointed as a Director. During her tenure, Danièle has supported
the Company in the realization of several major structural
operations and I am delighted to continue to benefit from her
support on the Board of Directors. The appointment of Dr. Shefali
Agarwal as Chair marks a new stage in the development of Onxeo,
resolutely focused on creating value through the clinical
demonstration of the interest of our approach to DDR."
About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a
clinical-stage biotechnology company developing innovative oncology
drugs targeting tumor DNA-binding functions through unique
mechanisms of action in the sought-after field of DNA Damage
Response (DDR). The Company is focused on bringing early-stage
first-in-class or disruptive compounds from translational research
to clinical proof-of-concept, a value-creating inflection point
appealing to potential partners.
platON™ is Onxeo’s chemistry platform of oligonucleotides
acting as decoy agonists, which generates new innovative compounds
and broaden the Company’s product pipeline.
AsiDNA™, the first compound from platON™, is a
first-in-class, highly differentiated clinical stage candidate in
the field of DNA Damage Response (DDR). Its decoy and agonist
mechanism acting upstream of multiple DDR pathways results in
distinctive antitumoral properties, notably the ability to prevent
or abrogate tumor resistance to targeted therapies such as PARP
inhibitors and a strong synergy with tumor DNA-damaging agents such
as radio/chemotherapy. AsiDNA™ is currently in combination clinical
studies in hard-to-treat solid tumors.
OX401 is a new drug candidate from platON™, optimized to
be a potent PARP agonist acting on both the DNA Damage Response and
the activation of immune response, without inducing resistance.
OX401 is undergoing preclinical proof-of-concept studies, alone and
in combination with immunotherapies.
For more information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties
and other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a
discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements,
please refer to the risk factors described in the most recent
Company’s registration document or in any other periodic financial
report and in any other press release, which are available free of
charge on the websites of the Company Group (www.onxeo.com) and/or
the AMF (www.amf-france.org).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210729005808/en/
Onxeo Valerie Leroy, Investor Relations
investors@onxeo.com +33 1 45 58 76 00
Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu
+33 1 44 71 94 98
Investor Relations / Strategic Communication Dušan
Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94
92
Certified Adviser for Nasdaq First North Kapital Partner
www.kapitalpartner.dk info@kapitalpartner.dk +45 89 88 78 46